News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

ALL CONTRIBUTIONS

Week In Review: Tianjin CanSino Staging $160.5 Million Hong Kong IPO
Tianjin CanSino Biologics, a vaccine company, expects to raise up to $160.5 million in a Hong Kong IPO, which will begin trading on March 28. The company is developing 15 vaccine candidates for 12 disease areas.
Read
Week In Review: Inventis Closes $70 Million Financing To Develop 30 Novel Therapeutics
InventisBio of Shanghai closed a $70 million Series C financing led by Advantech Capital and CMBI, followed by Pudong Innotek. Founded in 2013, InventisBio focuses on discovering and developing novel therapeutics for cancer and metabolic diseases.
Read
Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS
Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Chinese blood plasma company Shanghai RAASfor $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in Grifols Diagnostic Solutions for the RAAS stake.
Read
Week In Review: Nanjing's NJCTTQ Agrees To $4 Billion Package For Abpro Bi-Specific Immunotherapies
NJCTTQ, a Nanjing biopharma, announced a deal worth up to $4 billion to co-develop bispecific immunotherapies discovered by Abpro of Massachusetts.
Read
Week In Review: Sciwind, A Hangzhou Biopharma, Raises $29.5 Million For NASH Treatments
Hangzhou Sciwind Biosciences completed a $29.5 million series A round, led by Legend Capital. Sciwind develops protein and peptide candidates for non-alcoholic steatohepatitis (NASH) and the diseases it causes, including diabetes and liver fibrosis.
Read
Week In Review: CStone's Hong Kong IPO To Raise $304 Million At $1.5 Billion Valuation Next Week
China will reduce the Value Added Tax on 21 rare disease treatments to 3%, starting March 1. Plus: an IPO, financings, licensing, funding rounds.
Read

STOCKS I FOLLOW

AXN Aoxing Pharmaceutical Company, Inc.
CRPNF China Pioneer Pharma Holdings Ltd.
CYIG CHINA YCT INTL GROUP
HCM Hutchison Chi-Med
ICLR Icon PLC
MCRPF MICROPORT SCIENTIFIC
MDCO The Medicines Company
MR Mindray Medical International Limited
NBY NovaBay Pharmaceuticals, Inc.
SCLN SciClone Pharmaceuticals, Inc.
WX WuXi PharmaTech Inc.
Load More

TWEETS

LATEST ACTIVITY

ChinaBio® Today
Week In Review: Tianjin CanSino Staging $160.5 Million Hong Kong IPO $MRK https://t.co/NakRBJr5rc...

ChinaBio® Today
Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS $CASI $CASI $BGNE $GRFS $NVO https://t.co/rf0rbGpcBR less
ChinaBio® Today
Week In Review: Nanjing's NJCTTQ Agrees To $4 Billion Package For Abpro Bi-Specific Immunotherapies $ASLN $ASLN $BCAC https://t.co/YKQB33roae less
All Posts

PERSONAL BLOG

Latest Posts

Work Experience

Education

Publications